Normal plasma homocysteine levels range from 4 to 15 µmols/L, but 5% to 12% of the general population has mildly elevated levels (hyperhomocysteinemia). High homocysteine is considered as a risk factor for several vascular diseases, including heart disease, and is also implicated in retinal disorders, including retinal vein occlusion, endothelial cell dysfunction,
37 and disruption of retinal pigment epithelium.
38,39 Patients with diabetes generally present high plasma homocysteine levels, and the levels can go up to 50 to 100 µmols/L,
11,40 and clinical studies have shown a strong correlation between hyperhomocysteinemia and diabetic retinopathy.
40,41 In physiological conditions, homocysteine and H
2S regulate each other,
13 however, in patients with diabetes and animal models, plasma H
2S levels are significantly lower.
42,43 Our previous study has shown greater than threefold elevation in retinal homocysteine in human diabetic donors with documented retinopathy compared to without retinopathy, and approximately twofold decrease in H
2S levels.
16 Here, we show that retinal H
2S levels are significantly lower in diabetic mice, and administration of a slow releasing H
2S donor, in addition to preventing decrease in H
2S, prevents the development of histopathology characteristic of diabetic retinopathy. In addition, GY also inhibits diabetes-induced retinal vascular leakage in these mice. In support, GY is shown to prevent retinal vascular leakage and abnormalities in retinal function in mice lacking
CBS,
44 and its intravitreal administration preserves ganglion cells from acute ischemic injury and optic nerve crush, and by dilating retinal vessels, improves their perfusion.
45 In diabetes, GY protects accelerated atherosclerosis and inhibits inflammasome activation.
46 Supplementation with H
2S donor, sodium hydrosulfide (NaHS), in diabetic rat model improves retinal vascular permeability, neuronal dysfunction, and thickness,
47 and in the rat glaucoma model, provides neuroprotection and attenuates ganglion cell apoptosis.
48